Treatment
GLP-1 Receptor Agonists clinical trials
We’re tracking 53 recruiting studies that include GLP-1 Receptor Agonists, each written for real people, not researchers, below.
Recruiting studies
- NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT06654219Recruiting
Clear liquids before endoscopy for patients on GLP-1 meds
This study tests whether drinking only clear liquids before an upper endoscopy can reduce leftover stomach contents in people taking GLP-1 medications (like Ozempic or Mounjaro). It may help make the procedure safer.
Houston, TexasAges 18 years+ - NCT06324461RecruitingPhase 4
GLP-1 drug to protect heart after non-emergency surgery
This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.
Hong Kong, Hong Kong SARAges 18 years+ - NCT07484061Recruiting
Drinkable supplement for hair loss in women on weight-loss drugs
This trial tests if a special drinkable supplement can help prevent or reduce hair loss in women who are taking a GLP-1 or GIP receptor agonist (a type of weight-loss or diabetes medication). The study looks for women who have just started this medication or have been on it for less than 3 months.
Madrid, MadridAges 35 years+ - NCT07736963Recruiting
Stopping GLP-1 drugs before colonoscopy: a trial in Taiwan
This study looks at whether stopping GLP-1 receptor agonists (a type of diabetes or weight-loss medication) before a colonoscopy can help improve the procedure. It compares how well the bowel is cleaned in people who stop these drugs for a certain time versus those who continue them.
New Taipei, TaiwanAges 18–90 - NCT07736911RecruitingPhase 3
Should you pause your diabetes medication before a stomach scope?
This trial is testing whether stopping GLP-1 receptor agonists or tirzepatide one week before an upper endoscopy (a scope that looks at your stomach and esophagus) is safe and effective. It's designed for people who are already taking these medications and have an upcoming procedure.
New Taipei City, TaiwanAges 18–90 - NCT07720414Recruiting
GLP-1 Meds and Breastfeeding Study
This study tests whether a type of diabetes/weight loss medication (GLP-1 RA, given as a shot) affects milk production in breastfeeding mothers. It may help women who need this medicine while nursing.
Aurora, ColoradoAges Any age - NCT07740291Recruiting
Tirzepatide and lifestyle study for weight loss
This trial compares two ways to manage weight: taking a GLP-1 medication (like tirzepatide or semaglutide) versus making lifestyle changes without medication. It will help researchers learn which approach works best for people with overweight or obesity.
Lubbock, TexasAges 18 years+ - NCT07728669Recruiting
Digital diet app for people on GLP-1 therapy
This study tests a smartphone app that gives dietary advice to people who are overweight or obese and also take a GLP-1 medication (like semaglutide) for weight or diabetes. The app will help you follow a healthy eating plan while using the medication.
AlmatyAges 21–65 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99 - NCT07703683Recruiting
Muscle health in metabolic and hormone diseases
This trial looks at how muscle health is affected by metabolic or hormone disorders, aiming to find better markers for muscle loss called sarcopenia.
Woluwe-Saint-Pierre - Sint-Pieters-WoluweAges 18 years+ - NCT07702461Recruiting
Resistance training survey for people on weight loss meds
This trial is an online survey to understand how people taking GLP-1 medications (like Ozempic or Wegovy) are doing with resistance training. If you're an adult on a stable dose of a GLP-1 med for weight or diabetes, your input can help shape better exercise advice.
Columbus, OhioAges 18 years+ - NCT05356104RecruitingPhase 2
GLP-1 treatment to slow small blood-vessel brain damage
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Wenzhou, ZhejiangAges 55–80 - NCT06069622Recruiting
How a gene affects weight-loss treatment response
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
Boston, MassachusettsAges 18 years+ - NCT06132477RecruitingPhase 4
Study of GLP-1 medicines after weight loss surgery
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
Columbia, MissouriAges 18 years+ - NCT06256419Recruiting
Gene testing and exenatide response in Chinese type 2 diabetes patients
This study looks at how certain genes affect the risk of type 2 diabetes and how well the drug exenatide (a GLP-1 receptor agonist) works in Chinese patients. It aims to see if your genetic makeup can predict how you will respond to treatment.
Xuzhou, ChinaAges 25–70 - NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT07307235RecruitingPhase 4
Comparing a new diabetes combination to standard care for type 2 diabetes
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
Hefei, AnhuiAges 18 years+ - NCT06774079RecruitingPhase 4
GLP-1 drug and diet study for Crohn's disease patients
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
Miami, FloridaAges 18 years+ - NCT06839248Recruiting
Fasting before procedures with GLP-1 meds
This study looks at whether people taking weekly GLP-1 medications (like Ozempic or Wegovy) should follow standard fasting rules or a 24-hour clear liquid diet before a procedure. The goal is to find the safest way to prepare.
Melbourne, VictoriaAges 18 years+ - NCT06889454Recruiting
Heart and blood vessel changes in women with PCOS after treatment
This trial looks at how the heart's blood vessels and certain markers change in women with PCOS when they drink a sugary solution (OGTT). It checks these markers before treatment starts and again 6 and 12 months after, to help understand cardiovascular risk in PCOS.
ChaïdáriAges 18–45 - NCT06903923RecruitingPhase 2
Bone health in teens and young adults taking GLP-1 weight loss drugs
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
Charlottesville, VirginiaAges 12–21 - NCT06976619RecruitingPhase 2
Blood sugar control and a diabetes drug on insulin production
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
Rochester, MinnesotaAges 25–70 - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+
What GLP-1 Receptor Agonists is being studied for
Conditions with recruiting GLP-1 Receptor Agonists studies.
Common questions
- Are there clinical trials studying GLP-1 Receptor Agonists?
- Yes. Clin2 currently lists 53 recruiting studies that include GLP-1 Receptor Agonists, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a GLP-1 Receptor Agonists trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is GLP-1 Receptor Agonists an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether GLP-1 Receptor Agonists or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.